FOLFIRI

FOLFIRI is a chemotherapy regimen for treatment of colorectal cancer. It is made up of the following drugs:[1]

  • FOL – folinic acid (leucovorin), a vitamin B derivative used as a "rescue" drug for high doses of the drug methotrexate, but increases the cytotoxicity of 5-fluorouracil;
  • F – fluorouracil (5-FU), a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops synthesis; and
  • IRI – irinotecan (Camptosar), a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating.

Medical uses

FOLFIRI is used for colorectal cancer and gastric cancer.[2] FOLFIRI is effective in the treatment of metastatic colorectal cancer, but it has not been shown to be effective in the adjuvant therapy of colon and rectal cancer.

Regimen

The regimen consists of:

  • irinotecan (180 mg/m2 IV over 90 minutes) concurrently with folinic acid (400 mg/m2 [or 2 x 250 mg/m2] IV over 120 minutes)
  • followed by fluorouracil (400–500 mg/m2 IV bolus) then fluorouracil (2400–3000 mg/m2 intravenous infusion over 46 hours).

This cycle is typically repeated every two weeks. The dosages shown above may vary from cycle to cycle.

Combinations

FOLFIRI is often combined with bevacizumab, aflibercept, cetuximab or panitumumab to improve efficacy and response rate.[3]

Adverse effects

In the short term, irinotecan causes diarrhea, which may be acute or delayed in onset. Long term use of irinotecan may lead to neutropenia.[4]

See also

References

  1. ↑ Chen, K; Gong, Y; Zhang, Q; Shen, Y; Zhou, T (2016). "Efficacy and safety of addition of bevacizumab to FOLFIRI or irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer: A meta-analysis". Medicine. 95 (46): e5221. doi:10.1097/MD.0000000000005221. PMC 5120901. PMID 27861344.
  2. ↑ Tournigand, C; André, T; Achille, E; Lledo, G; Flesh, M; Mery-Mignard, D; Quinaux, E; Couteau, C; Buyse, M; Ganem, G; Landi, B; Colin, P; Louvet, C; de Gramont, A (Jan 15, 2004). "FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study". Journal of Clinical Oncology. 22 (2): 229–37. doi:10.1200/jco.2004.05.113. PMID 14657227.
  3. ↑ Kirstein, M. M.; Lange, A.; Prenzler, A.; Manns, M. P.; Kubicka, S.; Vogel, A. (2014). "Targeted Therapies in Metastatic Colorectal Cancer: A Systematic Review and Assessment of Currently Available Data". The Oncologist. 19 (11): 1156–68. doi:10.1634/theoncologist.2014-0032. PMC 4221380. PMID 25326159.
  4. ↑ "Onivyde: EPAR – Product Information" (PDF). European Medicines Agency. 25 October 2016.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.